Second-Line Chemotherapy for Recurrent Germ Cell Tumors After BEP
For patients with recurrent germ cell tumors after first-line BEP chemotherapy, four cycles of TIP (paclitaxel, ifosfamide, cisplatin) or VeIP (vinblastine, ifosfamide, cisplatin) represent the standard conventional-dose salvage regimens. 1
Primary Salvage Regimen Options
The ESMO guidelines explicitly designate both TIP and VeIP as conventional-dose salvage chemotherapy regimens for recurrent disease 1. The specific dosing is:
TIP Regimen (4 cycles, every 3 weeks):
- Paclitaxel 250 mg/m² IV on Day 1
- Cisplatin 25 mg/m² IV on Days 2-5
- Ifosfamide 1.5 g/m² IV on Days 2-5 (with mesna protection)
VeIP Regimen (4 cycles, every 3 weeks):
- Vinblastine 0.11 mg/kg IV on Days 1-2
- Ifosfamide 1.2 g/m² IV on Days 1-5 (with mesna 400 mg/m² every 8 hours)
- Cisplatin 20 mg/m² IV on Days 1-5
High-Dose Chemotherapy Consideration
For select patients, particularly those with poor prognostic features at relapse, high-dose chemotherapy with stem cell rescue should be considered 1. The guidelines describe two high-dose approaches:
TI-CE Protocol:
- Two cycles of TI (paclitaxel 200 mg/m² Day 1, ifosfamide 2.0 g Days 2-4) every 2 weeks for stem cell harvesting
- Followed by three cycles of CE (carboplatin AUC 7 Days 1-3, etoposide 400 mg/m² Days 1-3) with stem cell support at 14-21 day intervals
CE Protocol:
- Carboplatin 700 mg/m² Day 1
- Etoposide 750 mg/m² Days 1-3
- Two cycles with stem cell support, may be preceded by cytoreductive VeIP
Decision Algorithm
Choose conventional-dose salvage (TIP or VeIP) when:
- First relapse after complete response to first-line therapy
- Late relapse (>2 years after initial treatment)
- Limited disease burden at recurrence
Consider high-dose chemotherapy with stem cell rescue when:
- Refractory disease (progression during first-line therapy)
- Early relapse (<2 years)
- Incomplete response to first-line treatment
- Multiple adverse prognostic factors present
Critical Prognostic Factors at Salvage
The evidence identifies four adverse prognostic factors that should guide treatment intensity 2:
- High serum HCG (>10,000 mIU/mL) or AFP (>1,000 ng/mL)
- Extragonadal primary origin
- Presence of lung metastases at salvage
- Incomplete response to first-line treatment
Patients with multiple adverse factors should be strongly considered for high-dose chemotherapy approaches or referral to specialized centers 3, 4.
Important Caveats
- VIP (etoposide, ifosfamide, cisplatin) is also listed as a salvage option 1, though the guidelines more specifically designate TIP and VeIP for salvage after BEP failure
- All salvage therapy should ideally be delivered at high-volume specialized centers, as significant outcome disparities exist between high-volume and low-volume centers 3
- Conventional-dose salvage achieves approximately 20-30% long-term disease-free survival, while high-dose approaches may increase this to 40-45% in appropriately selected patients 5, 2
- Rising tumor markers during salvage indicate progressive disease requiring highly specialized multidisciplinary therapy 1